Benzinga | Jan 11, 2022 06:36AM EST

CVS To Raise FY21 Adj. EPS Guidance From $8.00+ To $8.33-$8.38 vs $8.03 Est.; Will reaffirm FY22 Adj. EPS Guidance Of $8.10-$8.30 vs $8.27 Est.

Members of CVS Health Corporation's ("CVS Health's" or the "Company's") senior management team are scheduled to participate in a webcast at 8:15 a.m. (Eastern Time) and meet with investors on January 11, 2022. During the webcast and meetings, the Company will disclose that it has raised its full year 2021 GAAP diluted earnings per share ("EPS") guidance range to $5.87 to $5.92 from $5.50 to $5.61 and raised its full year 2021 Adjusted EPS guidance range to $8.33 to $8.38 from at least $8.00. The Company will also affirm its full year 2022 GAAP diluted EPS guidance range of $7.04 to $7.24 and its Adjusted EPS guidance range of $8.10 to $8.30.



An audio and video webcast of the presentation will be broadcast simultaneously for all interested parties through the Investor Relations portion of the CVS Health website at http://investors.cvshealth.com. The accompanying presentation materials will be available on the website shortly before the presentation begins and archived for one year along with a replay of the webcast.



Our financial closing procedures for the full year 2021 are not yet complete and, as a result, our actual results may change as a result of such financial closing procedures, final adjustments, management's review of results, and other developments that may arise between now and the time our financial results for the full year 2021 are finalized, and our results could be outside of the ranges set forth above and different than the estimates in the table below.